Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.

@article{Kruse2008AnalysisOC,
  title={Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.},
  author={Gregory B Kruse and Mayur M. Amonkar and Gregory Smith and Dean C Skonieczny and Spyros Stavrakas},
  journal={Journal of managed care pharmacy : JMCP},
  year={2008},
  volume={14 9},
  pages={844-57}
}
BACKGROUND An estimated $8.1 billion (in 2004 dollars) is spent annually on total health care costs for the treatment of breast cancer in the United States. Breast cancer has traditionally been treated with intravenous (IV) cancer therapies that entail not only the drug acquisition cost, but additional costs of personnel time, supplies, and equipment used in the preparation and administration of the IV drug. A systematic study of the costs of IV administration in the metastatic breast cancer… CONTINUE READING